Publications by authors named "N N Lomakin"
Article Synopsis
- Patients with severe COVID-19 pneumonia have limited treatment options, and opaganib is an oral medication being researched to help those hospitalized.
- A clinical trial conducted in 57 locations from August 2020 to July 2021 compared opaganib to a placebo over 14 days, focusing on whether patients could stop needing supplemental oxygen by day 14.
- Although the primary results showed no significant general benefit, post-hoc analysis indicated that patients with low oxygen levels at baseline may experience better outcomes with opaganib, including reduced intubation rates and lower mortality, suggesting the need for further studies in this specific group.
Aim: To evaluate the impact of frailty syndrome (FS) on the course of acute decompensated heart failure (ADHF) and the quality of drug therapy before discharge from the hospital in patients with reduced and moderately reduced left ventricular ejection fraction (LVEF).
Material And Methods: This open prospective study included 101 patients older than 75 years with reduced and mid-range LVEF hospitalized for decompensated chronic heart failure (CHF). FS was detected during the outpatient follow-up and identified using the Age is Not a Hindrance questionnaire, the chair rise test, and the One Leg Test.
The State Research Center of Virology and Biotechnology "VECTOR" of the Federal Service for the Oversight of Consumer Protection and Welfare (Rospotrebnadzor) has developed the peptide-based EpiVacCorona vaccine, which is the first synthetic peptide-based antiviral vaccine for mass immunization in international vaccinology. An early clinical trial (Phase I-II) demonstrated that the EpiVacCorona vaccine is a safe product. The "Multicenter double-blind, placebo-controlled, comparative, randomized trial to assess the tolerability, safety, immunogenicity and prophylactic efficacy of the EpiVacCorona COVID-19 vaccine based on peptide antigens in 3000 volunteers aged 18 years and older" was performed regarding vaccine safety.
View Article and Find Full Text PDFThe Advisory Board chaired by the chief specialist in infectious diseases of the Ministry of Health of Russian Federation, Professor V.P. Chulanov was held on June 18, 2022 in Saint Petersburg.
View Article and Find Full Text PDFBackground. Despite the fact that COVID-19 usually manifests with severe pneumonia, there is a growing body of evidence that life-threatening multiorgan damage is caused by vascular and hemostatic abnormalities. Since there is no established therapy, assessing antithrombotics is indeed important.
View Article and Find Full Text PDF